publications
Home >
publications

publications

Publications

  1. R Xu, YJ Lee, CH Kim, GH Min, YB Kim, JW Park, DH Kim, JH Kim, H Yim* (2023) Invasive FoxM1 phosphorylated by PLK1 induces the polarization of tumor-assoicated macrophages to promote immune escape and metastasis, amplified by IFITM1. J. Exp. Clin. Cancer Res. 42(1):302. doi: 10.1186/s13046-023-02872-1.
  2. DE Kim, SB Shin, CH Kim,  YB Kim, HJ Oh,  H Yim* (2023) PLK1-mediated phosphorylation of beta-catenin enhances its stability and transcriptional activity for extracellular matrix remodeling in metastatic NSCLC. Theranostics 13 (3): 1198-1216. doi: 10.7150/thno.79318.
  3. DH Kim, NY Song, H Yim* (2023) Targeting dysregulated lipid metabolism in the tumor microenvironment (2023) Arch. Pharm. Res. doi: 10.1007/s12272-023-01473-y.
  4. DE Kim, HE Byeon, DH Kim, SG Kim*, H Yim* (2023) Plk2-mediated phosphorylation and translocalization of Nrf2 activates anti-inflammation through p53/Plk2/p21cip1 signaling in acute kidney injury. Cell Biol. Toxicol. 39(4):1509-1529. doi: 10.1007/s10565-022-09741-1.
  5. CH Kim, DE Kim, DH Kim, GH Min, JW Park, YB Kim, CK Sung, H Yim* (2022) Mitotic protein kinase-driven crosstalk of machineries for mitosis and metastasis. Exp Mol Med. 54(4):414-425. doi: 10.1038/s12276-022-00750-y. 

  6. HR Hang, SB Shin, CH Kim, JY Won, R Xu, DE Kim, H Yim* (2021) PLK1/ vimentin signaling facilitates immune escape by recruiting Smad2/3 to PD-L1 promoter in metastatic lung adenocarcinoma. Cell Death Differ. 28: 2745-2764.

  7. SB Shin, DH Kim, DE Kim, MBD Aldonza, Y Kim, H Yim* (2021) Dual Targeting of EGFR with PLK1 Exerts Therapeutic Synergism in Taxane-Resistant Lung Adenocarcinoma by Suppressing ABC Transporters. Cancers 13(17): 4413, doi: 10.3390/cancers13174413. 

  8. SB Shin, HR Jang, R Xu, JY Won, H Yim* (2020) Active PLK1-driven metastasis is amplified by TGF-β signaling that forms a positive feedback loop in non-small cell lung cancer. Oncogene 39(4):767-785.
  9. CK Sung, H Yim* (2020) CRISPR-mediated promoter de/methylation technologies for gene regulation. Arch. Pharm. Res. 43: 705-713.
  10. SB Shin, CH Kim, HR Jang, H Yim* (2020) Combination of inhibitors of USP7 and PLK1 has a strong synergism against paclitaxel resistance. Int. J. Mol. Sci. 21 (22): 8629.
  11. R Xu, JY Won, CH Kim, DE Kim, H Yim* (2019) Roles of the phosphorylation of transcriptional factors in epithelial-mesenchymal transition. J Oncol. 2019:5810465. doi: 10.1155/2019/5810465.
  12. SB Shin, SU Woo, H Yim* (2019) Cotargeting Plk1 and androgen receptor enhances the therapeutic sensitivity of paclitaxel-resistant prostate cancer. Ther. Adv. Med. Oncol. 11:1758835919846375. doi: 10.1177/1758835919846375.
  13. MS Joo, SB Shin, EJ Kim, JH Koo, H Yim*, SG Kim* (2019) Nrf2-lncRNA controls cell fate by modulating p53-dependent Nrf2 activation as an miRNA sponge for Plk2 and p21cip1. FASEB J. 33(7): 7953-7969. 
  14. HS Chae, R Xu, JY Won, YW Chin, H Yim* (2019) Molecular targets of genistein and its related flavonoids to exert anticancer effects. Int. J. Mol. Sci. 20 (10) pii: E2420.
  15. SU Woo, HR Jang, YW Chin, H Yim* (2019) 7-O-methylwogonin from Scutellaria baicalensis disturbs mitotic progression by inhibiting Plk1 activity in Hep3B cells. Planta Med. 85(3) 217-224.
  16. H Kim, H Yim* (2018) 53BP1: A guardian for centrosomal integrity. Frontiers in Bioscience-Landmark 23(1) 1-12.
  17. SB Shin, SU Woo, Y-W Chin, Y-J Jang, H Yim* (2017) Sensitivity of TP53-mutated cancer cells to the phytoestrogen genistein is associated with direct inhibition of Plk1 activity. J. Cell. Physiol. 232(10) 2818-2828.
  18. MS Joo, JH Koo, SB Shin, H Yim, SG Kim (2017) Oligopeptide competition assay for phosphorylation site determination. J. Vis. Exp. 123. doi:10.3791/55708.
  19. SB Shin, SU Woo, YJ Lee, H Yim* (2017) Comparative Analysis of a FRET-based PLK1 Kinase Assay to Identify PLK1 inhibitors for Chemotherapy. Anticancer Res. 37 (3): 1177-1183. 
  20. CK Sung, H Yim* (2017) Roles of SALL2 in tumorigenesis. Arch. Pharm. Res. 40 (2) 146-151.
  21. H Yim*, SB Shin, SU Woo, PC Lee, RL Erikson (2017) Plk1-mediated stabilization of 53BP1 through USP7 regulates centrosome positioning to maintain bipolarity. Oncogene 36, 966-978.
  22. YM Han, SU Woo, MS Choi, YN Park, SH Kim, H Yim*, HH Yoo* (2016) Antiinflammatory and analgesic effects of Eurycoma longifolia extracts. Arch. Pharm. Res. 39(3):421-8.
  23. SB Shin, SU Woo, H Yim*(2015) Differential cellular effects of Plk1 inhibitors targeting the ATP-binding domain or polo-box domain. J. Cell. Physiol. 230(12)3057-67.
  24. CK Sung, H Yim* (2015) The tumor suppressor protein p150(Sal2) in carcinogenesis. Tumor Biology 36(2): 489-94.
  25. ISHwang, SU Woo, JW Park, SK Lee, H Yim* (2014) Two nuclear export signals of Cdc6 are differentially associated with CDK-mediated phosphorylation residues for cytoplasmic translocation. Biochim. Biophys. Acta Mol. Cell Res. 1843 (2): 223-33.
  26. H Yim * and RL Erikson. (2014) Plk1-targeted therapies in TP53- or RAS-mutated cancer. Mutation Research Review in Mutation Research 761,31-39.
  27. SJ Lee, JW Hwang, H Yim, HJ Yim, SU Woo, SJ Suh, JJ Hyun, SW Jung, JS Koo,, JH Kim, YS Seo, JE Yeon, SW Lee, KS Byun, SH Um (2014) Synergistic effect of simvastatin plus NS398 on inhibition of proliferation and survival in hepatocellular carcinoma cell line.  J. Gastroenterology and Hepatology 29(6)1299-307.
  28. L Liu, H Yim, JH Choi, ST Kim, Y Jin, SK Lee (2014) ATM kinase promotes both caspase-8 and caspase-9 activation during TNF-a-induced apoptosis of HeLa cells. FEBS letters 588(6):929-35.
  29. HE Yim, H Yim, ES Bae, SU Woo, KH Yoo (2014) Predictive valute of urinary and serum biomarkers in young children with febrile urinary tract infections. Pediatric Nephrology 29(11):2181-9.
  30. CK Sung, H Yim, E Andrews, TL Benjamin (2014) A mouse polyomavirus-encoded microRNA targets the cellular apoptosis pathway through Smad2 inhibition. Virology 468-470:57-62.
  31. Hyuk-Jin Cha and Hyungshin Yim* (2013) The accumulation of DNA repair defects is the molecular origin of carcinogenesis. Tumor Biology 34 (6):3293-302.
  32. Hyungshi Yim(2013) Current clinical trials with polo-like kinase 1 inhibitors in solid tumors. Anti-cancer Drugs 24(10):999-1006
  33. Hyungshin Yim*, Park JW, Woo SU, Kim ST, Liu L, Lee CH, Lee SK. (2013) Phosphorylation of Cdc6 at serine 74, but not at serine 106, drives translocation of Cdc6 to the cytoplasm. J. Cell. Physiol. 228(6):1221-8. *Corresponding author
  34. Chang K. Sung*, Hyungshin Yim*, Hongcang Gu, Dawei Li, Erik Andrews, Sekhar Duraisamy, Cheng Li, Ronny Drapkinand Thomas L. Benjamin. (2012) The Polyoma Virus Large T Binding Protein p150 Is a Transcriptional Repressor of c-MYC. PLoS One 7(9): e46486. *Co-first author

  35. Xiao-Xi Guo , Hanna Kim, Yang Li, Hyungshin Yim, Seung Ki Lee, Ying-Hua Jin. (2011) Cdk2 acts upstream of mitochondrial permeability transition during paclitaxel-induced apoptosis. Protein Cell 2(7):543-53.

  36. Hyungshin Yim, Chang K. Sung, John You, Tian You, and Thomas L. Benjamin. (2011) NeK1 and TAZ models of polycystic kidney disease are linked through phosphorylation and ubiquitination. J. Am. Soc. Nephrol. 22(5) 832-837.
  37. Hyungshin Yim and Raymond L. Erikson. (2011) Regulation of the final stage of mitosis by com-ponents of the pre-replicative comples and a polo kinase. Cell Cycle 10 (9). 1374-1377.
  38. Hongcang Gu, Dawei Li, Chang K. Sung, Hyungshin Yim, Philip Troke and Thomas Benjamin. (2011) DNA-binding properties of the transcription factor and putative tumor suppressor p150sal2. Biochimica et Biophysica Acta - Gene Regulatory Mechanism 1809 (4-6), 276-283.
  39. Chang K. Sung, Jean Dahl, Hyungshin Yim, Scott Rodig, Thomas L. Benjamin. (2011) Transcrip-tional and post-translational regulation of the quiescence factor and putative tumor suppressor p150Sal2. FASEB J. 25(4): 1275-83.
  40. Hyungshin Yim* and Raymond L. Erikson*. (2010) Cdc6. A Mitotic Substrate and Partner of PIK1, Regulates Chromosomal Segregation Mediated by Cdk1-separase. Proc. Natl. Acad. Sci USA 107(46):19742-7. *Co-corresponding author
  41. Linhua Liu, Jae Hyuk Choi, Hyungshin Yim, joon-seok Choi, Byoung Duck Park, Seung Ju Cho, Seung Ki Lee (2009) ATR (AT mutated Rad3 related) activity stabilizes Cdc6 and delays G2/M-phase entry during hydroxyurea-induces S-phase arrest of HeLa cells. Int J. of Biochem. Cell Biol. 41 (6):1410-20.
  42. Hyungshin Yim* and Raymond L. Erikson (2009) Polo-like kinase-1 depletion induces DNA damage in early S prior to caspase activation. Mol. Cell. Biol. 29 (10): 2609-2621. *Correspond-ing author
  43. Joon-Seok Choi, Soona Shin, Ying Hua Jin, Hyungshin Yim, Kyo-Tan Koo, Kwang-Hoon Chun, You-Take Oh, Won Hee Lee, Seung ki Lee. (2007) Cyclin-dependent protein kinase 2 activity is required for mitochondrial translocation of Bax and disruption of mitochondrial transmembrane potential during etoposide-induced apoptosis. Apoptosis 12 (7): 1229-41.
  44. Young-Mi Ham, Jin-Hee Lim, Joon-Seok Choi, Byoung-Duck Park, Hyungshin Yim, Seung-Ki Lee. (2006) Ginsenoside-RH2 induces mitochondrial depolarization that is associated with ROS-and Ca2+-mediated JNK1 activation during apoptosis. J. Pharmacology and Experimental Therapeutics. 319 (3): 1276-1285.
  45. Hyungshin Yim, In Seon Hwang, Joon Seok Choi, Kwang Hoon Chun, Ying Hua Jin, Young-Mi Ham, Kwang Youl Lee, and Seung Ki Lee (2006) Caspase-3-cleavage of Cdc6 induces ATM/ATR kinase-mediated apoptosis of HeLa cells. J. Cell Biol. 174 (1): 77-88.
  46. Yong Woong Kim, Kyo Tan Koo, Joon Seok Choi, Ying Hua Jin, Hyungshin Yim, You Take Oh, and Seong Ki Lee. (2005) Analysis of cylcin-dependent kinase2-regulated phosphorylation of Stath-min in etoposide-induced apoptotic HeLa cells by two-dimensional electrophoresis and mass spectrometry. J. Health Sci., 51: 224-232.
  47. Hyungshin Yim, Ying Hua Jin, Byoung Duck Park, Hye Jin Choi, and Seung Ki Lee (2003) Caspase-3-mediated Cleavage of Cdc6 Induces Nuclear Localization of p49-truncated Cdc6 and Apoptosis. Mol. Biol. Cell, 14 (1): 4250-4259.
  48. Ying Hua Jin, Hyungshin Yim, Jeong Hill Park, and Seung Ki Lee. (2003) Cdk2 activity is associ-ated with depolarization of mitochondrial membrane potential during apoptosis. Biochem. Biophy. Res. Comm., 305 (4): 974-980.
  49. Hyungshin Yim, Yong Hee Lee, Chul Hoon Lee, and Seung Ki Lee. (1999) Emodin, an Anthraqui-none Derivative Isolated from the Rizomes of Rheum pheum palmatum, Selectively Inhibits the Activity of Casein Kinase II as a Competitive Inhibitor. Planta Medica 65 (1): 9-13.

Patents

  1. Hyungshin Yim and Hay-Ran Jang(2023.09.27) Pharmaceutical composition for preventing or treating cancer comprising a shRNA for inhibiting vimentin expression as an active ingredient. Korean Intellectual Property Office.The Patent Number  #10-2585460.
  2. Hyungshin Yim and Hay-Ran Jang (2023.03.15) Pharmaceutical composition for preventing or treating cancer comprising a vimentin mutant or a vector expressing the same as an active ingredient. Korean Intellectual Property Office.The Patent Number #10-2511660.
  3. Hyungshin Yim , Hay-Ran Jang, and Solbi Shin. (2022.11.07)  Pharmaceutical composition for treating metastatic cancer. Korean Intellectual Property Office.The Patent Number #10-2466691.
  4. Hyungshin Yim and Solbi Shin. (2022.04.21) Pharmaceutical composition for combination therapy with anticancer drug. Korean Intellectual Property Office.The Patent Number #10-2390586.
  5. Hyungshin Yim and Solbi Shin. (2021.01.25) Composition for treating metastatic cancer. Korean Intellectual Property Office.The Patent Number #10-2209537.
  6. Hyungshin Yim and Solbi Shin. (2020.06.15) Novel usage of 53BP1. Korean Intellectual Property Office. The Patent Number #10-2125005.
  7. Hyungshin Yim, Sang-Uk Woo, Young-Won Chin. (2016. 11. 16) Usage of genistein as an anticancer drug in p53-mutated solid tumors or paclitaxel-resistant cancer. Korean Intellectual Property Office. The Patent Number #10-1678791
  8. Seung Ki Lee and Hyungshin Yim. (2009. 04. 21) Screening method for apoptotic regulator using ATM/ATR. Korean Intellectual Property Office. The Patent Number # 10-0895256
  9. Seung Ki Lee and Hyungshin Yim. (2008. 10. 16) Apoptotic inhibitor of uncleavable Cdc6 mutaion protein and apoptotic inducer containing Cdc6 deleted protein. Korean Untellectual Property Office. The Patent Number # 10-0864870.
  10. Seung Ki Lee and Hyungshin Yim. (2006. 3. 22) Apoptotic inducer containing deleted proteins of Cdc6. Korean Intellectual Property Office. The Patent Number # 10-0565699.
Desktop Mode
Useful Sites
Hanyang University College of Pharmacy 55 Hanyangdaehak-ro, Ansan, Kyeonggi-do, 15588, Korea Lab of Molecular PharmacologyTEL +82-31-400-5810 FAX. +82-31-400-5958 E-mail: hsyim@hanyang.ac.kr

Copyright (c) 2016 Hanyang University. All Rights Reserved.

TOP
 
사이트맵 닫기